HC Wainwright Reiterates Buy Rating for InspireMD (NYSEAMERICAN:NSPR)

HC Wainwright reissued their buy rating on shares of InspireMD (NYSEAMERICAN:NSPR) in a research report sent to investors on Monday morning, AnalystRatings.com reports. HC Wainwright currently has a $5.00 price objective on the medical equipment provider’s stock.

Separately, Zacks Investment Research raised shares of InspireMD from a sell rating to a hold rating in a research note on Thursday, October 17th.

Shares of NYSEAMERICAN NSPR traded down $0.04 during trading on Monday, hitting $0.84. The company had a trading volume of 55,433 shares, compared to its average volume of 168,813. The firm’s fifty day simple moving average is $2.42. InspireMD has a fifty-two week low of $0.82 and a fifty-two week high of $12.00.

A hedge fund recently bought a new stake in InspireMD stock. Wedbush Securities Inc. purchased a new stake in InspireMD Inc (NYSEAMERICAN:NSPR) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 30,000 shares of the medical equipment provider’s stock, valued at approximately $39,000. Wedbush Securities Inc. owned 2.14% of InspireMD as of its most recent filing with the SEC.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.

Further Reading: What is meant by holder of record?

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.